Decitabine

1:34
The importance of quickly spotting the signs of AML
Srdan Verstovsek
4:19
Intervening on time: how hypomethylating agents can prevent transition to AML
Srdan Verstovsek
3:05
Current research in elderly, untreated AML: venetoclax combinations
Marina Konopleva
2:57
Genetic biomarkers of response to venetoclax in AML
Marina Konopleva
3:20
Venetoclax combinations effective in elderly AML
Marina Konopleva
1:39
Current landscape and future directions for lower-risk MDS treatment
David Steensma
1:06
Is there hope for treating TP53-mutated MDS?
Mark Levis
1:12
Hypomethylating agents for low risk MDS
Eunice Wang
1:58
Maintenance therapy strategies to reduce relapse in AML
Charles Craddock
2:50
Epigenetic therapies in AML: current and future landscape
Andrew Wei
1:54
Promising results for venetoclax across multiple hematological malignancies
Giovanni Martinelli
1:32
Encouraging patients to participate in AML trials
Eytan Stein
2:20
The complications of treating elderly patients with AML
Gail Roboz
2:33
Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
Farhad Ravandi
1:55
Ruxolitinib plus decitabine in post-MPN AML
Farhad Ravandi
2:01
AML: data to look forward to in 2018 and beyond
Richard Stone
The content of VJHemOnc is intended for healthcare professionals